This research study is evaluating new mutations that develop after treatment with targeted therapies in patients with lung cancer that is positive for a marker called “KRAS”.
KRAS-positive lung cancer is a subtype of lung cancer which carries a change in a gene called KRAS. There are now drugs for patients with KRAS-positive lung cancer that slow cancer growth. However, after some time, KRAS-positive lung cancers evolve ways to avoid the therapies by developing new mutations so the drugs lose their effectiveness. A deeper understanding of the biology behind resistance to KRAS inhibitors has the potential to inform future lines of therapy and novel combinations for individuals with KRAS driven lung cancer.
We are now able to detect the presence of mutations or changes in the genetic structure in lung cancer by analyzing a patient’s blood for bits of material shed by tumor. This approach is often called a liquid biopsy. Obtaining liquid biopsies on patients with KRAS-positive lung cancers at resistance to therapy may help us better understand the different mutations that develop and guide therapy decisions.
In this research study, we will collect a blood specimen and submit it for liquid biopsy analysis at a commercial diagnostic company. Specifically, we will look for genetic changes in the KRAS gene that could help understand why a cancer has developed drug resistance. You will not have to have a tissue biopsy to participate in this study. You do not have to visit our facility to participate. All study procedures will be performed remotely.
You are invited to take part in this research study, because you have KRAS-positive lung cancer and have been on a KRAS targeted treatment such as sotorasib or adagrasib.
Click on topic below for more information.